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Abstract
Background: Multidrug resistant and extensively drug resistant tuberculosis (TB) have become major threats to control of
tuberculosis globally. The rates of anti-TB drug resistance in Uganda are not known. We conducted a national drug
resistance survey to investigate the levels and patterns of resistance to first and second line anti-TB drugs among new and
previously treated sputum smear-positive TB cases.
Methods: Sputum samples were collected from a nationally representative sample of new and previously treated sputum
smear-positive TB patients registered at TB diagnostic centers during December 2009 to February 2011 using a weighted
cluster sampling method. Culture and drug susceptibility testing was performed at the national TB reference laboratory.
Results: A total of 1537 patients (1397 new and 140 previously treated) were enrolled in the survey from 44 health facilities.
HIV test result and complete drug susceptibility testing (DST) results were available for 1524 (96.8%) and 1325 (85.9%)
patients, respectively. Of the 1209 isolates from new cases, resistance to any anti-TB drug was 10.3%, 5% were resistant to
isoniazid, 1.9% to rifampicin, and 1.4% were multi drug resistant. Among the 116 isolates from previously treated cases, the
prevalence of resistance was 25.9%, 23.3%, 12.1% and 12.1% respectively. Of the 1524 patients who had HIV testing 469
(30.7%) tested positive. There was no association between anti-TB drug resistance (including MDR) and HIV infection.
Conclusion: The prevalence of anti-TB drug resistance among new patients in Uganda is low relative to WHO estimates. The
higher levels of MDR-TB (12.1%) and resistance to any drug (25.3%) among previously treated patients raises concerns about
the quality of directly observed therapy (DOT) and adherence to treatment. This calls for strengthening existing TB control
measures, especially DOT, routine DST among the previously treated TB patients or periodic drug resistance surveys, to
prevent and monitor development and transmission of drug resistant TB.
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Introduction
Tuberculosis (TB) remains one of the world’s leading causes of
adult morbidity and mortality resulting in an estimated 8.8 million
incident cases and 1.4 million deaths in 2010. Ninety-two percent
of the cases occur in low and middle-income countries. Sub-
Saharan Africa (SSA), a region with highest incidence of TB in the
world hosts nine of the highest TB incidence countries globally [1].
The STOP TB strategy developed by the World Health
Organization (WHO) aims to dramatically reduce the global
burden of tuberculosis by 2015 by ensuring that all TB patients
benefit from universal access to high-quality diagnosis and patient-
centered treatment [2]. The HIV epidemic and the emergence of
drug- resistant TB pose a serious challenge to achieving these
ambitious goals. Treatment of multidrug resistant TB (MDR-TB)
which is TB occurring in patients with strains of Mycobacterium
tuberculosis resistant to at least rifampicin and isoniazid, was
estimated to cost almost 30–40 times more than treatment of drug-
sensitive disease in a recent study done in South Africa. In addition
MDR-TB requires longer treatment with more toxic drugs, poorer
treatment success rates, prolonged periods of morbidity and higher
mortality as compared to drug sensitive TB [3,4].
MDR-TB is gaining global importance with an estimated
440,000 cases occurring annually, representing about 3.6% of all
TB cases across the world [5,6]. Inappropriate drug regimens,
non-adherence to treatment, transmission in congregate settings,
substandard drug quality, and erratic drug supply are the major
risk factors for development of drug resistant TB [7]. Mortality
rates among MDR-TB patients have been reported to be as high
as 37% and 89% among HIV-negative and HIV-positive patients
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respectively [8,9]. Anti-TB drug resistance surveillance using
routine drug susceptibility testing (DST) for all TB patients prior to
starting their TB treatment would be ideal for monitoring the
performance of TB control programs. However, due to the lack of
routine DST services in most high TB prevalent countries,
periodic surveys of representative samples of TB patients in the
country are the only available source of information on the
prevalence of anti-TB drug resistance. Despite the importance of
these periodic surveys, the most recent WHO reports show that
only 22 of the 46 countries in the African region have conducted
these anti-TB drug resistance surveys [10]. Some studies have
shown an association between HIV infection with rifampicin
monoresistance [11]and MDR-TB outbreaks have been associated
with HIV, although evidence showing HIV as an established
independent risk factor for MDR is not yet documented [12]. The
emergence of extensively drug resistant (XDR) TB, that is MDR-
TB strains resistant to any fluoroquinolone and at least one of
three injectable second-line drugs (i.e, amikacin, kanamycin, or
capreomycin) and its association with high mortality among people
living with HIV has raised a new challenge for TB control [13].
Uganda with an estimated population of 33 million ranks 19th
among the 22 high-TB burden countries in the world with an
estimated incidence of 209/100,000 for all forms of TB [1]. About
8% of all the notified cases have had previous exposure to anti-TB
drugs (relapses, defaulters or treatment failures). According to the
WHO global report 2011, the cure rate was 31%, treatment
completion 48%, death 8%, treatment failure 1% and treatment
default 12%, among previously treated sputum smear-positive
patients started on treatment. While among new patients, 28%
were cured, 42% completed treatment, 5% died, 1% failed, 11%
defaulted and approximately 14% were not evaluated.
Since 1997 Uganda has been using an eight-month regimen
with two months of isoniazid, rifampicin pyrazinamide and
ethambutol, followed by six months of isoniazid and ethambutol.
For previously treated sputum smear-positive TB patients, the
treatment regimen is two months of streptomycin, rifampicin,
ethambutol, isoniazid and pyrazinamide, one month of rifampicin,
ethambutol, isoniazid and pyrazinamide and 5 months of
rifampicin, isoniazid and ethambutol. The mainstay of TB
treatment in Uganda is community-based directly observed
treatment (DOT). The National TB Leprosy Program initiated
routine anti-TB drug resistance surveillance among re-treatment
cases in 2008 although this has not been adequately implemented
and improvement is still needed.
Limited anti-TB drug resistance surveys have been conducted
so far, one in 1996–97 as part of global drug resistance surveillance
that covered 3 zones. Two of the studies included new TB patients
where the prevalence of MDR-TB was found to be 0.5% and
1.1% respectively [14–16]. Data on national anti-TB drug
resistance rates and patterns in Uganda do not exist. The present
study is the first national anti-tuberculosis drug resistance survey in
Uganda conducted in accordance with the WHO-recommended
methodology [17]. The objectives of this survey were to establish
the prevalence of anti-TB drug resistance among new and
previously treated smear positive TB patients and to assess the
risk for anti-TB drug resistance among HIV-infected TB patients
in the country.
Methods
Study Design
We obtained ethical approval from the ethical board at the
Makerere University College of Health Sciences, the Uganda
National Council of Science and technology, and Associate
Director for Science at the United States, Centers for Disease
Control & Prevention. All adult patients gave written informed
consent before enrollment. Patients below 18 years assented and
their consent was provided by guardians/parents.
Sampling
A cluster sampling method was used in which 30 clusters
(primary sampling units) were selected randomly with probability
proportional to the number of smear-positive TB patients
registered in 2005. Within each cluster a fixed number of
consecutively diagnosed smear-positive patients were enrolled so
that all included patients had identical sampling probabilities
(‘‘self-weighted sampling design’’) [18]. Four hundred and ninety
eight public health facilities in Uganda had TB diagnostic and
treatment centers in 2007. We used data reported in these facilities
to determine the average number of TB patients diagnosed per
facility. The sample size was based on the number of new sputum-
smear positive TB cases notified through the National TB and
Leprosy Control Program (NTLP) in 2007 (n= 20,559) and
designed to detect an assumed rifampicin prevalence of 1.4% [15]
with 1% absolute precision for a 95% confidence interval (CI).
Assuming a design effect of 2, estimated losses due to contami-
nation and negative cultures of 15%, the final sample size was
1500 new sputum smear-positive patients with each cluster
required to enroll 50 patients within a year.
A cluster was defined as a health care facility that was able to
meet the requirement of 50 new smear-positive TB cases in a year
(according to the 2007 enrollment). Where a facility was noted to
have achieved enrollment of less than 50 new cases, it was merged
with others depending on proximity to each other to have a group
that was able to enroll the required minimum number of 50 cases.
Such a group was called a pseudo-cluster. Clusters and pseudo-
clusters were then listed. Based on the cumulative total enrollment
30 clusters/pseudo-clusters were selected randomly with proba-
bility proportional to the number of smear positive TB patients in
accordance with the WHO guidelines [18]. Participants were
enrolled from 44 diagnostic facilities [fig. 1]. Of these 21 were
clusters involving 18 facilities (one had four clusters) and 9 were
pseudo clusters involving 26 facilities. TB patients who were
already on anti-TB treatment at the beginning of the study were
excluded and enrollment of eligible patients into the study was
done alongside provision of other services involved in treatment
initiation including registration of patients in the unit TB registers
for care. Consecutive eligible and consenting patients were
enrolled in the survey until the sample size for each cluster was
met. Alongside enrollment of new cases, all sputum- smear positive
previously treated TB cases identified at the selected health
facilities during this period were also included in the survey.
Health care workers used a detailed questionnaire to collect
demographic and clinical information to accurately classify
patients as new or previously treated. Prior to the start of the
survey, staff from all the selected health facilities were trained on
the survey procedures and data instruments and participated in
the piloting of instruments. A national coordination team was
established to oversee and implement the survey.
Data Collection
A standard clinical form was used to obtain data on patients’
demographic characteristics, HIV status prior to enrollment and
previous history of TB treatment through a structured interview.
In addition data about risk factors for exposure to resistant strains
including imprisonment and those related to the patients’ social
environment were collected. All TB patients at the sites including
those eligible for enrollment were counseled and tested for HIV
Anti-Tuberculosis Drug Resistance in Uganda
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under routine conditions as required by the Uganda NTLP
guidelines [19] and their results were included in the information
sent on the case report form.
The national coordination team independently carried out re-
interviews on patients randomly selected from the enrolled patients
within 2 months of the original interview to validate their
treatment history in order to allocate each patient to the correct
category based on previous treatment.
Laboratory Methods
Sputum collection &transportation. Each eligible patient
who consented provided two sputum samples, an early morning
and spot sample, independent of the routine samples used for
diagnostic purposes to minimize chances of contamination of
samples collected for the survey. No decontaminants were added.
Samples were refrigerated at 4uC and then transported to the
National TB Reference Laboratory (NTRL) for processing via a
local courier system. Sputum samples were accompanied by a
sputum shipment form that contained information about the date
of sputum collection, participant number, and laboratory serial
number and quantified results of sputum smear examination from
the local laboratory.
Sputum culture and drug Susceptibility Testing
(DST). At the NTRL, samples were decontaminated using
1.5% NaOH NALC method. One of the samples, preferably an
early morning sample was processed while the other was kept as a
backup. The backup sample was analyzed if the first sample
turned out as either negative or contaminated. The other sample
was inoculated on 2 slopes of egg based Lowenstein-Jensen (L-J)
medium, incubated at a temperature of 37uC and monitored
weekly for growth up to 8 weeks. A culture was only reported
negative if no growth was shown after 8 weeks. For the positive
cultures identification of M. tuberculosis was done based on
presumptive phenotypic appearance of colonies on the medium,
Figure 1. Map showing Health care facilties which participated in the National anti-TB drug resistance survey December 2009–
February 2011.
doi:10.1371/journal.pone.0070763.g001
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and confirmed using insertion sequence 6110-based PCR method
as previously described [20].
Isolates were tested for resistance to rifampicin, isoniazid,
ethambutol and streptomycin using the L-J proportional method,
in concentrations of 40 mg/ml for rifampicin, 0.2 mg/ml for
isoniazid, 2.0 mg/ml for ethambutol and 4.0 mg/ml for strepto-
mycin and all identified MDR-TB isolates were tested for
resistance to kanamycin and ofloxacin using the same method in
concentrations of 30 mg/ml & 2.0 mg/ml respectively.
We sent all rifampicin resistant isolates, a random sample of
isolates from retreatment patients that were susceptible to isoniazid
and rifampicin (n = 20) and a random sample of isoniazid resistant
isolates sensitive to rifampicin (n = 20) to the supra-national
reference laboratory (Borstel -Germany) for blinded external
quality assurance.
Definitions
A smear positive case in the study was defined as an individual
in which at least one sputum sample was positive, for acid fast
bacilli by direct Ziehl Neelsen staining. We defined a new patient
as one who had not received first line anti-TB drugs for more than
one month and previously treated if the patient had received first
line anti-TB treatment for more than one month.
An MDR-TB patient was defined as one whose sputum isolate
showed resistance to at least isoniazid and rifampicin while XDR-
TB was defined as an MDR-TB patient whose isolate demon-
strated resistance to kanamycin (as an injectable second line anti-
TB drug) and ofloxacin (as a fluoroquinolone).
Data Management
Data were double entered in epi-info V6, and discrepancies
were corrected using the raw data. Analysis was done in Stata v.10
(Stata/Corp. College Station TX USA/.) For comparison of
categorical variables we used the Chi-square test or the 2-sided
Fishers’ exact test where appropriate. Multivariate analysis was
done using logistic regression. We did all significance testing at 5%
confidence level.
The outcome was the proportion of patients with drug
resistance stratified by history of previous treatment calculated as
a proportion across all clusters after weighing for the exact
sampling probabilities for each new individual patient for whom
DST results were available. These sampling weights were
calculated as (number of patients in the cluster with DST
results/50).In all these calculations confidence intervals and p-
values were adjusted for cluster design by first-order Taylor
linearization and by second-order correlation of Rao and Scott of
the Pearson X2 respectively, as implemented by Stata svy
commands. [21].
Results
Of the 1537 patients enrolled at 44 health facilities, 1397
(90.7%) were new and 140 (9.3%) previously treated (fig. 2).
Enrollment rate for the new sputum smear positive cases was
93.1% (1397/1500). Nine of the 30 clusters failed to enroll the
required 50 new sputum smear positive patients due to insufficient
number of patients registered during the enrollment period. A
total of 1018 (66.2%) patients were male and the median age of the
enrolled patients was 34.6 years. The national coordination team
re-interviewed 130 (8.3%) patients to confirm their treatment
history and the categorization of the patients as new or
retreatment by the facilities was found to be completely accurate.
Culture Results, Table 1
Of 1537 enrolled patients, both LJ slants from 77 (5.0%) were
contaminated leaving. 1460 patients who had culture results that
were included in analysis. Of these, 127 (8.7%) were negative
while 8 isolates grew non-tuberculous mycobacteria (NTM). A
total of 1325 (90.5%) patients with culture-positive isolates
underwent DST including 1209 isolates from new and 116 from
previously treated patients. There was no statistically significant
difference with respect to age, sex, history of previous treatment,
and patient HIV status between patients who had culture- positive
results and patients who had negative/contaminated cultures.
Drug Resistance Prevalence, Table 2
Among 1209 enrolled new patients with DST data, the
prevalence of resistance to any of the drugs was 10.3% (n= 124;
95% (CI); 8.6–12.1). Any resistance to isoniazid was found in 60
(5.0%; 95% CI; 3.8–6.3), and to rifampicin in 23 (1.9%; 95% CI;
1.2–2.8) of the isolates, while 17 (1.4%; 95% CI; 0.80–2.2) showed
MDR-TB. Monoresistance to rifampicin was observed in 3
(0.24%) of the isolates.
Of the 116 previously treated patients, 53 (38.6%) had been
cured, 58 (41.4%) completed treatment, 17 (12.1%) defaulted, 2
(1.4%) were treatment failures, while treatment outcomes of 9
(6.4%) patients were unknown. Thirty one (25.9%, 95% CI; 18.1–
34.8) showed resistance to at least one drug. Any resistance to
isoniazid was observed in 27 (23.3%, 95% CI; 15.3–32.0) and to
rifampicin in 14 (12.1%; 95% CI, 6.7–19.4) patients. All the 14
(12.1%, 95% CI; 6.8–19.4) isolates resistant to rifampicin were
MDR.
Overall the prevalence of any resistance and MDR when new
and previously treated patients are combined was 11.6% (n= 154
95%; CI, 9.90–13.4) and 2.3% (n= 31; 95% CI 1.5–3.3)
respectively. Of the 31 MDR-TB cases 17 (54.8; 95% CI 36.0–
72.6) were resistant to all the four first line drugs. We found
monoresistance prevalence highest for streptomycin 3.7% (n= 49;
95% CI 2.7–4.8) and lowest for rifampicin 0.3% (n= 4; 95% CI,
0–0.7).
Out of the 73 samples sent to the SRL for external QA,
accuracy was 97.3% (n= 71) for isoniazid, rifampicin, and
streptomycin and 95.8% (n= 70) for ethambutol. All MDR-TB
cases were correctly identified with exception of one isolate that
turned out to be pan-susceptible on retesting.
Factors Associated with Drug Resistance, Table 3
Isolates from patients previously exposed to anti-TB drugs were
more likely to show anti-TB drug resistance (odds ratio (OR) 9.02;
95% CI; 3.4–23.3 p,0.001). In multivariate analysis we found
that patients enrolled in urban clusters were more likely to have
MDR-TB, compared to those from rural clusters (Adjusted OR
6.0; 95%CI 1.40–25.3; p = 0.02). We also found a significant
association between age and drug resistance; those.35 years were
more likely to have MDR-TB as compared to patients ,35 years
among new patients (OR 2.0; 95% CI; 1.0–4.30), while among the
previously treated patients this association was not significant
(OR=1). No other associated factors were identified. Of the 1537
patients enrolled, 1524 (99.1%) had HIV testing of whom 469
(30.7%, 95% CI; 28.4–33.1) tested positive. Among the 1313
patients with complete HIV and DST results, no significant
association was observed between HIV infection and any
resistance (OR 1.2, 95% CI; 0.8–1.7 p= 0.38), isoniazid resistance
(OR 1.2; 95%CI 0.76–2.1 p= 0.36) or MDR (OR 1.5; 95%CI,
0.52–2.5; p = 0.71)in a multivariate analysis.
Anti-Tuberculosis Drug Resistance in Uganda
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XDR Prevalence
All the 31 MDR isolates were tested for susceptibility to
kanamycin and ofloxacin to which all demonstrated complete
susceptibility showing absence of XDR among the study patients.
Discussion
This study is the first nationally representative anti-TB drug
resistance survey in Uganda and one of the studies done in Sub
Saharan Africa at a national scale. The survey showed an MDR-
TB prevalence of 1.4% and 12.1% among new and previously
treated sputum smear-positive TB patients respectively. Since
settings with an MDR-TB prevalence of less than 3% among new
patients are classified as having a low MDR-TB burden, [22] we
conclude that the prevalence of MDR-TB among new smear
positive patients in Uganda is low. MDR-TB among previously
treated TB cases however was moderately high (12.1%). The
prevalence of resistance to any of the first line anti-TB drugs,
among new (8.3%) and previously treated (25.9%) patients was
consistent with findings of a recent community based survey in
Kampala city as shown in our previous report [16]. Other
nationwide surveys in the region have observed the prevalence in
Figure 2. Flow Chart of patient enrollment in the National Anti-TB drug resistance survey in Uganda; December 2009–February
2011. Figure legend: **NTM=Non Tuberculous Mycobacteria.
doi:10.1371/journal.pone.0070763.g002
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the same range. The prevalence of any resistance among new and
previously treated patients was 8.3% and 20% respectively in the
United Republic of Tanzania [23]. A related survey done in
Rwanda showed an MDR-TB rate of 3.9% when new and
previously treated patients were combined as compared to the
2.3% that we report for the new and previously treated patients
together in this survey [24].
While it’s difficult to directly compare outcomes from different
countries, especially when surveys are conducted at different time
periods, the data from this survey show that levels of MDR-TB
among newly diagnosed smear positive TB patients in Uganda are
relatively low. This could potentially be attributed among other
things to the limited use of rifampicin only during the first 2
months (2EHRZ/6EH) for new TB cases who contribute over
90% of the disease burden, assuming a good adherence to TB
therapy. This is contrary to the earlier reports that shorter
duration of rifampicin may lead to increase in acquired resistance
[25]. However, we also acknowledge the lower treatment success
rate (70%) among new smear positive patients and the potential
role of a rifampicin lacking TB regimen for this lower success rate
[26]. In addition to the 17 cases identified as MDR-TB, an
additional 43 and 6 new smear positive cases were found to have
resistance to isoniazid and rifampicin respectively thus placing
these patients just one step away from developing MDR-TB. If the
national TB program plans to adopt 6 month TB regimen with 4
months of rifampicin during the continuation phase in the near
future, directly observed therapy and adherence to therapy for all
TB cases especially new TB cases has to be carefully monitored
and completion ensured. The higher rates among previously
treated TB patients as we see in this study have been attributed to
stepwise selection of mutants due to drug resistance conferring
genes [27]. Higher levels of MDR-TB (12.1%) and resistance to
any drug (25.3%) among previously treated patients raises
concerns about the quality of directly observed therapy and
adherence to treatment. XDR-TB was not detected among the
survey participants. Our study was not powered to assess the
prevalence of XDR-TB among the study participants so no
definitive conclusions could be made about the prevalence of
XDR-TB in the country. However, XDR-TB might be a very
limited problem if at all in Uganda especially given the limited use
and availability of the second line drugs. Disaggregated by age, the
older age group (.35 years) had higher levels of MDR-TB than
the young age group (OR 2.0; 95% CI; 1.0–4.30) implying higher
chances of exposure over time to drug-resistant TB in the
community by the older than the young population. Patients
diagnosed in urban clusters were more likely to have MDR-TB
(OR=6; 95% CI, 1.44–25.3 ) than those from rural facilities,
probably as a result of referral of complicated TB cases including
MDR-TB suspects from rural health units to referral centers
(regional/district hospitals) commonly located in urban areas.
Table 1. Demographic Characteristics of Patients enrolled in National anti-TB drug resistance survey in Uganda; December 2009–
February 2011.
Characteristic N (%) N=1537
Included for DST n (%)
N=1325
Not included for DST n (%)
N=212 p-value
Sex Male 1018 (66.2) 874 (66.5) 144 (67.9) 0.69
Female
Missing
507 (33.0)
12 (0.78)
439 (33.5)
12 (0.91)
68 (32.1)
–
Age 13–14 33 (2.2) 30 (2.30) 3 (1.42) 0.23
15–24 299 (19.5) 263 (19.9) 36 (17.0)
25–34 521 (33.9) 456 (34.4) 65 (30.7)
35–44 366 (23.8) 309 (23.3) 57 (25.9)
45–54 167 (10.9) 142 (10.7) 25 (11.8)
.55 139 (9.04) 113 (8.5) 26 (12.3)
Missing 12 (0.78) 12 (0.91) 0
HIV results Positive 469 (30.5) 399 (30.1) 70 (33.0) 0.28
Negative 1056 (68.7) 914 (69.0) 142 (66.9)
Missing 12 (0.78) 12 (0.91) 0
Previous history of TB
treatment
Yes 140 (9.1) 116 (8.7) 24 (11.3) 0.19
No 1385 (90.1) 1197(91.3) 188 (88.7)
Missing 12 (0.78) 12 (0.91)
N = 140 N=116
Outcome of previous
treatment
successful 53 (37.9) 44 (37.9) 9 (37.5) 0.97
unsuccessful 8762.1) 72(62.1) 15 (62.5)
unknown –
Homeless yes 2 (0.1) 2 (0.1) – –
Prisoner Yes 7 4 3 –
p-values for the patients included and those not included in the analysis of drug resistance.
doi:10.1371/journal.pone.0070763.t001
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Overcrowding in the towns and cities might also have facilitated
primary MDR-TB transmission resulting in majority of the cases
being in the urban clusters.
HIV prevalence was 30.7% (95% CI; 28.4–33.1) among study
participants was lower than the 54% found among all TB cases
through the TB surveillance system [1]. HIV was more prevalent
among female participants than among males (OR 1.89; 95%; CI
1.45–2.50; p=,0.01) and this finding was consistent with the
gender wise HIV prevalence in the general population. According
to the recent AIDS Indicator Survey (AIS) the HIV prevalence
among females aged 15–59 was 7.6% and 5.6% among men of the
same age group [28]. Like in other published studies, there was no
statistically significant association between HIV infection and
MDR-TB [29–32], although some studies have reported contrast-
ing findings in which such an association has been documented
[33].
Of major concern among the findings is the existence of
primary resistance (rifampicin 1.9%, isoniazid 5%, streptomycin
6.3%) implying ongoing transmission of drug resistant strains in
the community. This could imply weakness in infection control
measures which should therefore be strengthened through
dissemination of TB infection control guidelines by the NTLP.
Priority should also be accorded to TB infection control training
for health care workers in the TB diagnostic and treatment centers
especially those which offer comprehensive TB/HIV care. Health
care work was identified as a risk factor for resistance to any of the
anti-TB drugs according to our earlier report [16], suggesting that
nosocomial transmission of drug-resistant TB strains occurs.
Limitations
The survey only represented patients diagnosed through the
NTLP-supervised health facilities and does not account for drug
resistance patterns among population not having access to the
Table 2. Anti- tuberculosis Drug Resistance Among New and Previously Treated Sputum Smear- Positive TB patients in Uganda;
December 2009–February 2011.
New cases Previously Treated All cases
Pattern of Resistance Number (%) 95% CI Number (%) 95% CI Number (%) 95% CI
Total patients N=1209 N=116 1325
Susceptible to all 1085 (89.7) 87.9–91.3 86 (74.1) 65.2–81.8 1171 (88.4) 86.5–90.0
£Any Resistance 124 (10.3) 8.40–12.3 30 (25.9) 18.1–34.8 154 (11.6) 9.9–13.4
Any Resistance to;
RMP 23 (1.9) 1.2–2.8 14 (12.1) 6.80–19.4 37 (2.80) 1.9– 3.8
INH 60 (5.0) 3.8–6.3 27 (23.3) 15.9–32.1 87 (6.56) 5.2–8.0
EMB 25 (2.1) 1.3–3.0 13 (11.2) 6.10–18.4 38 (2.90) 2.0–4.0
SM 76 (6.3) 4.9–7.8 20 (17.2) 10.6–25.3 96 (7.24) 5.9–8.7
INH+RMP Resistant (MDR)
INH+RMP (Only) 3 (0.25) 0.0–0.6 2 (1.72) 0.2–6.1 5 (0.38) 0.1–0.8
INH+RMP+ EMB 0 (0) – 0 (0) – 0 (0) –
INH+ RMP+ SM 6 (0.5) 0.0–1.0 3 (2.6) 0.5–7.3 9 (0.68) 0.3– 1.2
INH+RMP+EMB+SM 8 (0.70) 0.1–1.3 9 (7.8) 4.0–14.2 17 (1.30) 0.7–2.0
All INH+RMP Resistant (MDR) 17 (1.40) 0.6–2.2 14 (12.1) 6.80–19.40 31 (2.3) 1.5–3.3
INH+ Other Resistance
INH+EMB 5 (0.38) 0.0–0.8
INH+ SM 12 (0.9) 0.4–1.4 6 (5.2) 1.9–10.0 18 (1.4) 0.8–2.1
INH+EMB+ SM 0 (0) – 0 (0) – (0) –
RMP+other Resistance
RMP+ EMB 0 (0) – 0 (0) – 0 (0) –
RMP+ SM 2 (0.21) 0.1–0.6 0 (0) – 2 (0.2) 0–0.5
RMP+ EMB+ SM 0 (0) – 0 (0) – 0 (0) –
¥Mono Resistance to;
RMP 3 (0.24) 0.0–0.7 0(0) – 4 (0.30) 0.0–0.7
INH 26 (2.1) 1.1–3.1 7 (6.0) 2.40–12.0 33 (2.5) 1.7–3.5
EMB 11 (0.9) 0.4–1.4 1 (0.9) 0.0–4.0 12 (0.9) 0.5–1.5
SM 47 (3.8) 2.7–5.0 2 (1.7) 0.2–6.1 49 (3.7) 2.7–4.8
Other Resistance
EMB+ SM 1(0.05) 0–0.2 0 (0) – 1 (0.1) 0–0.4
6RMP= rifampicin INH= isoniazid EMB= ethambutol SM= streptomycin.
£Any Resistance: Resistance to any of the anti TB drugs either in combination or as single drug.
¥Mono Resistance; Resistance to only one anti-TB drug.
doi:10.1371/journal.pone.0070763.t002
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health system and, we did not have data about the size and
characteristics of this patient population. Although the survey was
conducted using the most recent WHO guidance, smear negative
patients were not included in the survey. Our findings thus might
not account for potentially different drug resistance pattern among
smear negative TB patients. Moreover, inclusion of smear negative
patient who are more likely to be HIV positive might impact the
association between MDR-TB and HIV status. Nosocomial
transmission in congregate settings has been proven to be one of
the major risk factors for transmission of MDR-TB. We were not
able to assess it during this survey.
Also, the sampling frame was based on TB case notification in
2005 in Uganda, and a number of changes in health care delivery
system had taken place since, especially the establishment of new
districts and new health facilities, which did not make part of the
sampling frame but shared the patients with the included facilities.
Incidents of untimely closure of the local courier system in some
parts of the country might have led to delayed or non-delivery of
the sputum samples from these clusters which could have
contributed to the observed contamination and enrollment rates
that varied from expected. However to avoid selection bias due to
unequal participation rates, we controlled for this occurrence at
the analysis level by weighting for the exact sampling probabilities
for each individual patient for whom DST results were available
across the clusters. We could have done multiple imputation for
the missing drug resistance results, but with the amount of data
that were available to predict drug resistance status for missing
results, this method would most likely lead to biased results as well.
The distances covered to reach the nearest diagnostic/treatment
units (DTUs) in some clusters were too long to bring the early
morning sample after submission of the spot sample as the study
required. Some patients therefore failed to deliver the early
morning sample within the required period. These numbers were
however too small to affect the enrollment rates and the
occurrence was too random to result into any bias that could
significantly affect our results. Our conclusions about XDR-TB
prevalence were based on resistance studies against kanamycin
alone although cross resistance with other injectable second line
anti-TB drugs has been documented.
Conclusion and Recommendations
Anti-TB drug resistance among new smear positive TB cases
was low and not associated with HIV infection in Uganda, despite
the high TB-HIV co infection rates. We therefore recommend that
strengthening and implementation of appropriate interventions is
critical to keep MDR-TB levels low in the country or to reverse the
trends. The NTLP needs to focus on improving the quality of
directly observed therapy and develop interventions to support
patient adherence in order to prevent development of acquired
resistance. The NTLP should strengthen the existing specimen
referral system and implementation of a routine surveillance
system for anti-TB drug resistance to follow drug resistance trends
over time and to identify outbreaks of drug resistant TB.
Establishment of an effective MDR-TB control program and
treatment strategy would be critical for effective clinical manage-
ment of all cases of drug resistant TB. The introduction of rapid
molecular diagnostic tests like Xpert MTB/RIF present a unique
opportunity to diagnose MTB and identify rifampicin resistance
within 2 hours [34,35]. WHO recommends the use of Xpert
MTB/RIF as the first diagnostic test for persons at risk of
developing MDR-TB and among people living with HIV [36] and
NTLP should consider targeted roll out this technology. Efforts
towards TB infection control including ensuring adequate
ventilation for inpatient wards and outpatient waiting areas,
provision of protective wear for patients and most importantly
effective treatment of drug susceptible cases should be ensured to
minimize emergence of new MDR-TB cases. We recommend
further studies to establish whether MDR-TB cases are due to
reactivation of latent disease or transmission of new infections and
whether there exists predominance of a particular MTB strain
among drug resistant patients as described elsewhere [37].
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Table 3. Analysis of factors associated with Multi drug resistance in Uganda; December 2009–February 2011.
Risk Factor Univariate Multivariate
N (%) OR (95%CI) OR (95% CI)
Sex
Male 21/881 (2.4) 0.94 (0.4–2.0) 1.2 (0.50–3.30)
Female 10/444 (2.3)
Age group (years)
,35 9/757 (1.2)
$35 22/568 (3.9) 3.3 (1.5–7.0) 2 (1.0–4.3)
Residence Urban 28/798 (3.51) 6.3 (1.9–20.9) 6.0 (1.44–25.3)
Rural 3/527 (0.57)
Previous history of TB treatment Yes 14/116 (12.1) 8.6 (4.3–16.9) 8.6 (4.0–18.2)
No 17/1209 (1.4)
**HIV Status Positive 11/388 (2.8) 1.3 (0.6–2.6)
Negative 20/984 (2.2)
Variable included in the multivariate model were, age, sex, residence and previous history of TB treatment.
**Analysis limited to univariate level as inclusion at multivariate level masked the apparent association between MDR and potential risk factors.
doi:10.1371/journal.pone.0070763.t003
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